

## *Division of Signal Transduction Therapy*

### **Standard Operating Procedure**

#### **Preparation of active PI3 kinase alpha E542K [2 – 1068] / p85 [1 - 724]**

**Enzyme description:-** PI3 kinase alpha E542K [2 – 1068] / p85 [1 - 724]

**Clone number:-** DU 12756

**Source:-** Recombinant

**Expression system:-** Baculovirus expression vector system

**Tag:-** N-terminal His(6) PI3 kinase alpha  
No tag for p85

**Purification method:-** Ni<sup>2+</sup>-NTA agarose

**Expression level:-** 3 mg/L

#### **Calculated molecular mass:-**

Monoisotopic            125, 024.43 daltons [PI3kinase alpha] and 83, 546.54 daltons [P85]  
Average Mass            125, 106.00 daltons [PI3kinase alpha] and 83, 598.39 daltons [P85]  
[cysteines reduced, methionines have not been oxidised]

**Theoretical pI:-** 7.19 for PI3kinase alpha and 5.84 for P85

**Purity:-** >80 %

**Activation protocol:-** Constitutively active

#### **Enzyme storage buffer:-**

50mM Hepes/NaOH pH7.0, 150 mM NaCl, 5 mM DTT, 20 % glycerol

**Storage temperature:-** -70 °C

**Assay:-** ADP Glo

#### **Assay Buffer:-**

12.5 mM glycine-NaOH pH 8.5, 50 mM KCl, 1 mM DTT, 0.05 % CHAPS, 2.5 mM MgCl<sub>2</sub>

#### **Substrate:-**

PI (4,5)P<sub>2</sub>diC8            Final concentration: 0.05 mM

# *Division of Signal Transduction Therapy*

## Clone Data Sheet

### PI3 kinase alpha E542K [2 – 1068] / p85 [1 - 724]

<u>Protein</u>	PI3 kinase alpha [2 – 1068] / p85 [1 – 724]
<u>Clone number</u>	DU 12756
<u>Species</u>	Human
<u>Accession number</u>	PI3 kinase alpha U79143 / p85 NM_181523
<u>Tags</u>	N-terminal His(6)
<u>Baculovirus expressed</u> <u>PI3 kinase alpha</u>	MHHHHHHPPRPSSGELWGIHLMPPRILVECLLPNGMIVTLECLREATLI TIKH <del>E</del> LFKEARKYPLH <del>Q</del> LLQDESSYIFVSVTQEAEEREEFFDETRRLCDL RLFQPFLK <del>V</del> IEPVGNREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRR NILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQI IVVIWIVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSQI KLCVLEYQGKYILKVC <del>G</del> CDEYFLEK <del>K</del> PLSQYKYIRSCIMLGRMPNLMLM AKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWINSALRIK ILCATYVN <del>V</del> NIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEW LNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDT LVSGK <del>M</del> ANLWPVP <del>H</del> GLE <del>D</del> LLNP <del>I</del> GVTGSNP <del>N</del> KETPCLE <del>E</del> FDWFSSVV KFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKA ISTRDPLS <del>K</del> ITEQEKDFLW <del>S</del> HRHYCVTIPEILPK <del>L</del> LSVKWNSRDEVAQ MYCLVKDW <del>P</del> PIKPEQAMELLDCNYPDPMVRGF <del>A</del> VR <del>C</del> LE <del>K</del> YLTD <del>D</del> DKL <del>S</del> QY LIQLVQL <del>K</del> YEQYLDNLLVR <del>F</del> LLKKALT <del>N</del> Q <del>R</del> IGHFFF <del>W</del> HLKSEMHNKT <del>V</del> SQR <del>F</del> GLLLESYC <del>R</del> ACGMYLKHLNRQ <del>V</del> AMEKL <del>I</del> NLTD <del>I</del> LKQ <del>E</del> KKDET <del>Q</del> VQMKFLV <del>E</del> QMRRPDFMDALQGFLSPLNPAHQLGNLR <del>E</del> ECRIMSSAKRP LWLNWENPDIMSELLFQNNEIIFKNGDDL <del>R</del> QDM <del>L</del> T <del>Q</del> IIRIMENIWQ <del>Q</del> GLDLRMLPYG <del>C</del> L <del>S</del> IGDCVGLIEVVR <del>N</del> SHT <del>I</del> MQI <del>O</del> CK <del>G</del> GLKG <del>A</del> Q <del>F</del> NSHT LHQWLKDKNK <del>G</del> EIYDAAI <del>D</del> L <del>F</del> TRSCAGYCVAT <del>F</del> ILGIGDRHNSNIMV <del>K</del> DGQLFHIDFGHFLD <del>H</del> KKKKFGYKR <del>R</del> VP <del>V</del> L <del>T</del> QDFLIVISKGAQ <del>E</del> CT <del>K</del> REFERFOEMCYKAYLAIRQHANLF <del>I</del> NLF <del>S</del> MLGSGMPELQS <del>F</del> DDIAY <del>I</del> R KTLALDKTEQEALEYFMKQ <del>M</del> NDAHGGWTTKMDWIFHTIKQ <del>H</del> ALN
<u>Native sequence</u> <u>PI3 kinase alpha</u>	Amino acids P2 – N1068 (end) of human PI3 kinase alpha. Residue P8 of the fusion protein is equivalent to P2 of the native enzyme. The enzyme has a E542K mutation to mimic the activation mutation found in many types of cancers. Residues E542 is equivalent to K548 of the fusion protein. The His(6) tag is located at residues 2 – 7.

*Division of Signal Transduction Therapy*

Baculovirus  
expressed  
P85

MSAEGYQYRALYDYKKEREEDIDLHLDILTVNKGSIVALGFSDGQEAR  
PEEIGWLNGYNETTGERGDFPGTYVEYIGRKKISPPTPKPRPPRPLPVA  
PGSSKTEADVEQQALTLPDLAEQFAPPDIAPPLLIKLVIAIEKKGLECS  
TLYRTQSSNLAELRQLLDCDTPSVDEIMDVHVLADAFKRYLLDLPNP  
VIPAAYVSEMISSLAPEVQSSEEEYIQLLKKLIRSPSIPHQYWLTQYLLK  
HFFKLSQTSSKNLLNARVLSEIFSPMLFRFSAAASSDNTENLIKVIEILI  
STEWNERQPAPALPPKPKPTTVANNGMNNNMSLQDAEWYWGDISREEV  
NEKLRDTADGTFLVRDASTKMHGDYTLTLRKGGNNKLIKIFHRDGKYGF  
SDPLTFSSVVELINHYRNESLAQYNPKLDVKLLYPVSKYQDQVVKEDN  
IEAVGKKLHEYNTQFQEKSREYDRLYEEYRTSQEIQMRTAIEAFNET  
IKIFEEQCQTQERYSKKEYIEKFREGNEKEIQRIMHNYDKLKSRISEII  
DSRRRLEEDLKKQAAEYREIDKRMNSIKPDLIQLRKTRDQYLMWLTKKG  
VRQKQLNEWLGNENTEDQYSLVEDDEDLPHDEKTWNVGSSNRNKAENL  
LRGKRDGTFLVRESSKQGCYACSVVDGEVKHCVINKTATGYGFAEPYN  
LYSSLKELVLHYQHTSLVQHNDSLNVTLAYPVYAQQRR

Native sequence  
P85

Amino acids M1 – R724 (end) of human P85.

Cloning sites

*Xho*1 and *Kpn*1 (insert 1, PI3 kinase alpha) and  
*Bam*H1 and *Spe*1 (insert 2, P85) sites of pFastBAC Dual

## *Division of Signal Transduction Therapy*

**Complete  
nucleotide  
of sequence of PI3  
kinase alpha**

ATGCACCATCACCATCACCATCCTCCAAGACCATCATCAGGTGAACTGT  
GGGGCATCCACTGATGCCCAAGAACATCCTAGTAGAATGTTACTACC  
AAATGGAATGATAGTGACTTTAGAATGCCTCGTGAGGCTACATTATA  
ACCATAAAGCATGAACTATTAAAGAAGCAAGAAAATACCCCTCCATC  
AACTTCTCAAGATGAATCTTCTACATTTCTGAAGTGTACTCAAGA  
AGCAGAAAGGAAGAACATTGGATGAAACAAGACGACTTGTGACCTT  
CGGCTTTCAACCCTTTAAAAGTAATTGAACCAGTAGGCAACCGTG  
AAGAAAAGATCCTCAATCGAGAACATTGGTTGCTATCGGCATGCCAGT  
GTGTGAATTGATATGGTTAAAGATCCAGAAGTACAGGACTTCCGAAGA  
AATATTCTGAACGTTGAAAGAACGCTGTGATCTTAGGGACCTCAATT  
CACCTCATAGTAGAGCAATGTATGTCTATCCTCAAATGTAGAATCTTC  
ACCAGAATTGCCAAGCACATATATAATAAATTAGATAAAGGGCAAATA  
ATAGTGGTATCTGGTAATAGTTCTCAAATAATGACAAGCAGAAGT  
ATACTCTGAAAATCAACCATGACTGTGTACCAGAACAGTAATTGCTGA  
AGCAATCAGGAAAAAACTCGAAGTATGTTGCTATCCTCTGAACAACTA  
AAACTCTGTGTTTAGAATATCAGGGCAAGTATATTAAAAGTGTGTG  
GATGTGATGAATACTCCTAGAAAAATATCCTCTGAGTCAGTATAAGTA  
TATAAGAAGCTGTATAATGCTTGGGAGGATGCCAATTGATGTTGATG  
GCTAAAGAAAGCCTTATTCTCAACTGCCAATGGACTGTTACAATGC  
CATCTTATTCCAGACGCATTCCACAGCTACACCATATATGAATGGAGA  
AACATCTACAAAATCCCTTGGTTATAAATAGTGCACTCAGAATAAAA  
ATTCTTGTGCAACCTACGTGAATGAAATATTGAGACATTGATAAGA  
TCTATGTCGAACAGGTATCTACCATGGAGGAGAACCTTATGTGACAA  
TGTGAACACTCAAAGAGTACCTGTTCCAATCCCAGGTGGAATGAATGG  
CTGAATTATGATATATACATTCTGATCTCCTCGTGTGCTCGACTTT  
GCCTTCATTGCTCTGTTAAAGGCCAAAGGGTCTAAAGAGGAACA  
CTGTCCATTGGCATGGGAAATATAAACTGTTGATTACACAGACACT  
CTAGTATCTGGAAAATGGCTTGAATCTTGGCCAGTACCTCATGGAT  
TAGAAGATTGCTGAACCTATTGGTGTACTGGATCAAATCAAATAA  
AGAAACTCCATGCTTAGAGTTGGAGTTGACTGGTTCAGCAGTGTGGTA  
AAGTCCCAGATATGTCAGTGATTGAAGAGCATGCCAATTGGCTGTAT  
CCCGAGAAGCAGGATTAGCTATTCCACGCAGGACTGAGTAACAGACT  
AGCTAGAGACAATGAATTAAGGAAAATGACAAAGAACAGCTCAAAGCA  
ATTTCTACACGAGATCCTCTCTAAATCACTGAGCAGGAGAAAGATT  
TTCTATGGAGTCACAGACACTATTGTGTAACTATCCCCGAAATTCTACC  
CAAATTGCTCTGCTGTTAAATGGAATTCTAGAGATGAAGTAGCCCAG  
ATGTATTGCTGGAAAAGATTGGCTCCAATCAAACCTGAACAGGCTA  
TGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTCAGGTTTGC  
TGTCGGGCTTGGAAAATATTAAACAGATGACAAACTTCTCAGTAT  
TTAATTCACTGAGATTGACTGAGATGAACTGAGTACAAAGGATTGG  
TGCTTGTGAGATTGACTGAGAAAGCATTGACTATCAAAGGATTGG  
GCACTTTCTTGGATTAAACAGATGACAAACTTCTCAGTAT  
AGCCAGAGGTTGGCCTGCTTTGGAGTCCTATTGTCGTGCATGTGGGA  
TGTATTGAGACACTGAAATAGGCAAGTCGAGGCAATGGAAAAGCTCAT  
TAACTTAACGACATTCTAAACAGGAGAAGAAGGATGAAACACAAAAG  
GTACAGATGAAGTTTAGTTGAGGCAATGAGGCGACCAGATTGATGG  
ATGCTCTACAGGGCTTCTGCTCCTCTAAACCTGCTCATCAACTAGG

*Division of Signal Transduction Therapy*

AAACCTCAGGCTTGAAGAGTGTCAATTATGTCCTCTGCAAAAGGCCA  
CTGTGGTTGAATTGGGAGAACCCAGACATCATGTCAGAGTTACTGTTTC  
AGAACAAATGAGATCATCTTAAAAATGGGGATGATTACGGCAAGATAT  
GCTAACACTCAAATTATTCGTATTATGGAAAATATCTGGCAAATCAA  
GGTCTTGATCTCGAATGTTACCTTATGGTTGTCTGCAATCGGTGACT  
GTGTGGGACTTATTGAGGGGGTGCAGAAATTCTCACACTATTATGCAAAT  
TCAGTGCAAAGGGGGCTTGAAAGGTGCACTGCAGTTAACAGGCCACACA  
CTACATCAGTGGCTCAAAGACAAGAACAAAGGAGAAATATATGATGCAG  
CCATTGACCTGTTACACGTTACATGTCAGGATACTGTGTAGCTACCTT  
CATTGGAAATTGGAGATCGTCACAATAGTAACATCATGGTCAAAGAC  
GATGGACAACGTGTTCATATAGATTGGACACTTTGGATCACAAGA  
AGAAAAAAATTGGTTATAAACGAGAACGTGTCAGGATCACAAGAC  
GGATTCTTAATAGTAGTAAAGGAGCCAAGAACATGCACAAAGACA  
AGAGAATTGAGAGGTTAGGAGATGTGTTACAAGGCTTATCTAGCTA  
TTCGACAGCATGCCAATCTTCATAAATCTTCTCAATGATGCTTGG  
CTCTGGAATGCCAGAACTACAATCTTGATGACATTGCATACATTGCA  
AAGACCCTAGCCTAGATAAAACTGAGCAAGAGGCTTGGAGTATTCA  
TGAAACAAATGAATGATGCACATCATGGGGCTGGACAACAAAAATGGA  
TTGGATCTTCCACACAATTAAACAGCATGCATTGAACtggattacc

## *Division of Signal Transduction Therapy*

**Complete  
nucleotide  
of sequence of P85**

ATGAGTGCTGAGGGTACCACTACAGAGCGCTGTATGATTATAAAAAGG  
AAAGAGAAGAAGATATTGACTTGCACCTGGGTGACATATTGACTGTGAA  
TAAAGGGCCTTAGTAGCTCTGGATTCACTGATGGACAGGAAGCCAGG  
CCTGAAGAAATTGGCTGGTTAAATGGCTATAATGAAACCACAGGGAAA  
GGGGGGACTTCCGGAACTTACGTAGAATATATTGGAAGGAAAAAAAT  
CTCGCCTCCCACACCAAAGCCCCGCCACCTCGGCCTTCCTGTTGCA  
CCAGGTTCTCGAAAACCTGAAGCAGATGTTGAACAACAAGCTTGACTC  
TCCCGGATCTTGCAGAGCAGTTGCCCTCCTGACATTGCCCGCCTCT  
TCTTATCAAGCTCGTGGAGGCCATTGAAAAGAAAGGTCTGGAATGTTCA  
ACTCTATACAGAACACAGAGCTCCAGCAACCTGGCAGAATTACGACAGC  
TTCTTGATTGTGATACACCCCTCCGTGGACTTGGAAATGATCGATGTGCA  
CGTTTTGGCTGACGCTTCAAACGCTATCTCCTGGACTTACCAAATCCT  
GTCATTCCAGCAGCCGTTACAGTGAATGATTCTTAGCTCCAGAAG  
TACAAAGCTCCGAAGAATATATTCACTATTGAAAGAAGCTTATTAGGT  
GCCTAGCATACTCATCAGTATTGGCTTACGCTTACAGTATTGTTAAAA  
CATTCTCAAGCTCTCTCAAACCTCCAGCAAAATCTGTTGAATGCAA  
GAGTACTCTGAAATTTCAGCCCTATGCTTTCAGATTCTCAGCAGC  
CAGCTCTGATAACTGAAAACCTCATAAAAGTTATAGAAATTAACT  
TCAACTGAATGGAATGAACGACAGCCTGCACCAGCACTGCCTCTAAAC  
CACCAAAACCTACTACTGTAGCCAACAACGGTATGAATAACAATATGTC  
CTTACAAGATGCTGAATGGTACTGGGAGATATCTGAGGGAAAGAAGTG  
AATGAAAACCTCGAGATACAGCAGACGGGACCTTTGGTACGAGATG  
CGTCTACTAAAATGCATGGTGATTATACTCTACACTAAGGAAAGGGGG  
AAATAACAAATTAAATCAAATATTTCATCGAGATGGAAATATGGCTTC  
TCTGACCCATTAAACCTCAGTTCTGTTGAATTAAATAACCAACTACC  
GGAATGAATCTCTAGCTCAGTATAATCCAAATTGGATGTGAAATTACT  
TTATCCAGTATCCAAATACCAACAGGATCAAGTTGTCAAAGAAGATAAT  
ATTGAAGCTGTAGGGAAAAAATTACATGAATATAACACTCAGTTCAAG  
AAAAAAAGTCGAGAATATGATAGATTATGAAGAATATAACCCGCACATC  
CCAGGAAATCCAAATGAAAAGGACAGCTATTGAAGCATTAAATGAAACC  
ATAAAATATTGAAGAACAGTGCCAGACCCAAGAGCGGTACAGCAAAG  
AATACATAGAAAAGTTAACGTGAAGGCAATGAGAAAGAAATACAAAG  
GATTATGCATAATTATGATAAGTTGAAGTCTGAATCAGTGAATTATT  
GACAGTAGAAGAAGATTGGAAGAAGACTTGAAGAAGCAGGCAGCTGAGT  
ATCGAGAAATTGACAAACGTATGAACAGCATTAAACCAGACCTTATCCA  
GCTGAGAAAGACGAGAGACCAATACTTGATGTGGTTGACTCAAAAGGT  
GTTCGGCAAAAGAAGTTGAACGAGTGGTTGGCAATGAAAACACTGAAG  
ACCAATATTCACTGGTGGAAAGATGATGAAGATTGCCCCATCATGATGA  
GAAGACATGGAATGTTGGAAGCAGCAACCGAAACAAAGCTGAAAACCTG  
TTGCGAGGGAAAGCGAGATGGCACTTTCTGTCCGGGAGAGCAGTAAAC  
AGGGCTGCTATGCCTGCTGTAGTGGTGGACGGCGAAGTAAAGCATTG  
TGTCTAAACAAACAGCAACTGGCTATGGCTTGGCGAGCCCTATAAC  
TTGTACAGCTCTGAAAGAACTGGTGTACATTACCAACACACCTCCC  
TTGTGCAGCACAAAGACTCCCTCAATGTCACACTAGCCTACCCAGTATA  
TGCACAGCAGAGGCGAtgaactagt